Evaluation of Eravacycline: A Novel Fluorocycline

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

(2019) Amit Kaushik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration

(2019) Lindsay M. Avery et al.   CLINICAL THERAPEUTICS

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile

(2019) Eugenie Basseres et al.   Open Forum Infectious Diseases

Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?

(2018) Nicholas S. Britt et al.   AMERICAN JOURNAL OF INFECTION CONTROL

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species

(2018) EllieJ.C. Goldstein et al.   ANAEROBE

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

(2018) David R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits

(2018) Vidmantas Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus , Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA

(2018) Kieu-Nhi Tran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015

(2018) George G. Zhanel et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Upregulation of AcrEF in Quinolone Resistance Development in Escherichia coli When AcrAB-TolC Function Is Impaired

(2018) Chuan-Zhen Zhang et al.   Microbial Drug Resistance

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae

(2018) Sarah Christina Jane Jorgensen et al.   PHARMACOTHERAPY

The Rapid Emergence of Tigecycline Resistance in blaKPC–2 Harboring Klebsiella pneumoniae, as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment

(2018) Xiaoxing Du et al.   Frontiers in Microbiology

Tetracycline-Inactivating Enzymes

(2018) Jana L. Markley et al.   Frontiers in Microbiology

Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae

(2018) Jin-xin Zheng et al.   Emerging Microbes & Infections

Mass Balance and Drug Interaction Potential of IV Eravacycline Administered to Healthy Subjects

(2018) Joseph V. Newman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections

(2018) Joseph S Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential

(2017) P. R. S. Lagacé-Wiens et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Divergent Route to Eravacycline

(2017) Wu-Yan Zhang et al.   JOURNAL OF ORGANIC CHEMISTRY

Tigecycline Susceptibility and Molecular Resistance Mechanisms Among Clinical Klebsiella pneumoniae Strains Isolated During Non-Tigecycline Treatment

(2017) Ruilian Li et al.   Microbial Drug Resistance

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial

(2017) Joseph Solomkin et al.   JAMA Surgery

Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing Regimen

(2017) Patrick Horn et al.   Open Forum Infectious Diseases

Antibacterial Efficacy of EravacyclineIn Vivoagainst Gram-Positive and Gram-Negative Organisms

(2016) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii

(2016) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Eravacycline Pharmacokinetics and Challenges in Defining Humanized ExposureIn Vivo

(2016) Abrar K. Thabit et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline

(2016) Yunliang Zhang et al.   JOURNAL OF ANTIBIOTICS

Klebsiella pneumoniae: Going on the Offense with a Strong Defense

(2016) Michelle K. Paczosa et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Antibacterial drug discovery in the resistance era

(2016) Eric D. Brown et al.   NATURE

Eravacycline (TP-434) Is ActiveIn Vitroagainst Biofilms Formed by Uropathogenic Escherichia coli

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility Testing of Eravacycline Is Unaffected by Medium Age and Nonstandard Assay Parameters

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

(2015) James R. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Eravacycline (TP-434) Is Efficacious in Animal Models of Infection

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The β-Lactams Strike Back: Ceftazidime-Avibactam

(2015) Evan J. Zasowski et al.   PHARMACOTHERAPY

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

(2015) Keith S. Kaye et al.   PHARMACOTHERAPY

Activity of Eravacycline Against North American and European Enterobacteriaceae, Including Multidrug-Resistant Isolates, Collected in 2013–14

(2015) Ian Morrissey et al.   Open Forum Infectious Diseases

Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

(2014) Kevin P. Connors et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

(2014) Marie Abdallah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections

(2013) Joseph S. Solomkin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens

(2013) J. A. Sutcliffe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus

(2013) George Sakoulas et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development

(2013) Magnus Ronn et al.   ORGANIC PROCESS RESEARCH & DEVELOPMENT

New antibiotics for bad bugs: where are we?

(2013) Matteo Bassetti et al.   Annals of Clinical Microbiology and Antimicrobials

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

(2012) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials

(2012) P. Prasad et al.   CLINICAL INFECTIOUS DISEASES

The history of the tetracyclines

(2011) Mark L. Nelson et al.   Annals of the New York Academy of Sciences

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

(2011)   CLINICAL INFECTIOUS DISEASES

Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent

(2011) Xiao-Yi Xiao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature

(2010) Michael O. Griffin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Combined ramR Mutation and Presence of a Tn1721-Associated tet(A) Variant in a Clinical Isolate of Salmonella enterica Serovar Hadar Resistant to Tigecycline

(2009) M. Hentschke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs

(2009) J. L. Crandon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Correlation of Antimicrobial Resistance with  -Lactamases, the OmpA-Like Porin, and Efflux Pumps in Clinical Isolates of Acinetobacter baumannii Endemic to New York City

(2008) S. Bratu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES